Research from St. Jude Children's Research Hospital found a link between inherited BRCA2 mutations and an increased risk of childhood non-Hodgkin lymphoma. The study analyzed data from 1,380 lymphoma survivors and found that members with BRCA2 mutations were more likely to develop the disease.
A study by St. Jude Children's Research Hospital and Massachusetts General Hospital has revealed the cells of origin for four known subtypes of medulloblastoma, a malignant pediatric brain tumor. The researchers used single-cell RNA sequencing to shed light on the relationship between the subtypes and provided new insights into Group 4...
Researchers at St. Jude Children's Research Hospital have discovered an association between a mutation in the NEU1 gene and fibrotic conditions, including idiopathic pulmonary fibrosis. The study found that mice lacking the Neu1 gene developed muscle atrophy due to excessive connective tissue production.
St. Jude Children's Research Hospital scientists have determined the structure of the minichromosome maintenance complex, a ring-shaped enzyme that plays a central role in DNA replication. The research proposes a rotary mechanism to initiate DNA replication and may help solve one of biology's greatest mysteries.
St. Jude Children's Research Hospital scientists identified a pathway called LC3-associated endocytosis (LANDO) that clears β-amyloid protein, a hallmark of Alzheimer's disease. The discovery may lead to strategies for treating neurodegenerative disorders and malignant brain tumors.
Researchers at St. Jude Children's Research Hospital found that children with acute lymphoblastic leukemia mount a robust immune response to their cancer. The study suggests that the immune system may be able to effectively target pediatric ALL, potentially leading to new immunotherapy treatments.
Young cancer survivors with severe hearing loss experience significant declines in reading skills due to processing speed and phonological difficulties. Interventions focusing on neurocognitive and language-based skills can help improve reading mastery before tackling more complex tasks.
Abnormal necroptosis function contributes to cancer cell survival and multiple sclerosis, Parkinson's disease. Controlling necroptosis may lead to new treatments for these diseases.
Infants with X-linked severe combined immunodeficiency (SCID-X1) have been cured of the disease using gene therapy developed at St. Jude Children's Research Hospital. The treatment produced functional immune cells, including T cells and B cells, in all but one patient.
Researchers found that the most common genetic cause of ALS, C9orf72 mutation, leads to toxic dipeptide repeat polypeptides (DPRs) disrupting nucleolar assembly. Longer DPRs are more toxic to cells, highlighting a potential prognostic value for ALS patients.
St. Jude scientists discover that ULK1 and ULK2 break down stress granules, which build up toxic proteins that kill muscle and brain cells in diseases including IBM, ALS, and FTD. Boosting these enzymes could help treat the conditions.
A genetic study has identified a risk factor for stroke among childhood cancer survivors who received cranial radiation therapy. Variants in the chromosomal region 5p15.33 increase the risk of stroke approximately five-fold among those treated with intermediate dose radiation.
Researchers identified six age-related subgroups of acute erythroid leukemia with distinct mutations and patterns of gene expression. These findings suggest that genomic alterations can predict treatment outcomes, offering new insights into the diagnosis and treatment of this aggressive cancer.
The Cancer Control and Survivorship Program at St. Jude Children's Research Hospital has been awarded the 13th annual AACR Team Science Award for its innovative research advancing childhood cancer treatment and long-term survival outcomes. The program's work has significantly contributed to our understanding of pediatric cancer epidemi...
A Children's Oncology Group study shows that postoperative radiation improves outcomes for children with ependymoma, achieving seven-year progression-free survival for over 75% of patients and overall survival for 85%. The findings provide evidence that radiation can improve outcomes despite age and tumor subtype.
A study at St. Jude Children's Research Hospital identified MAP3K8 as the most commonly mutated gene in pediatric spitzoid melanoma, driving cancer growth and treatment response. Comprehensive genomic testing revealed novel mutations, including kinase fusions, that may be targeted by precision medicines.
Researchers at St. Jude Children's Research Hospital have identified genetic variations in ERG associated with an increased risk of acute lymphoblastic leukemia in Hispanic children. These variations were more common and had a stronger effect in Hispanic children than in other ethnic groups.
Researchers at St. Jude Children's Research Hospital developed a method to customize and reduce drug interaction alerts in electronic health records. The study made 26 changes that affected 47% of alerts, resulting in a 40% decrease in alert overrides.
The study identifies key areas for improvement in pediatric patient care, including high-reliability principles and early-warning systems. Stakeholders, including parents, played a crucial role in shaping the research agenda.
A new study led by St. Jude Children's Research Hospital found that high-risk leukemia patients did not experience improved long-term survival with bone marrow transplantation. Treatment guided by measuring minimal residual disease was associated with better outcomes, with 58% of patients becoming long-term survivors.
St. Jude Children's Research Hospital scientists identify 23 subtypes of B-cell acute lymphoblastic leukemia (B-ALL), including eight new subtypes, with distinct genomic and clinical features. The study's findings may lead to the development of precision medicines and customized treatments for high-risk patients.
Researchers present findings on acute erythroid leukemia, identifying five subtypes with distinct genomic features and survival rates. St. Jude also shares updates on gene therapy for hemophilia B and advances in sickle cell disease treatment.
Researchers found that common genetic variations can significantly increase breast cancer risk for female pediatric cancer survivors, with a two-fold higher risk compared to average survivors. The collective effect of these variations is comparable to having a high-risk mutation in breast cancer predisposition genes.
Researchers at St. Jude Children's Research Hospital have developed a new class of compounds called pantazines that may treat the rare neurodegenerative disorder pantothenate kinase-associated neurodegeneration (PKAN). The compounds elevate coenzyme A levels, preventing neuron dysfunction and improving symptoms in mice models.
Researchers from St. Jude Children's Research Hospital present comprehensive genomic profiling data from the Genomes for Kids study, showcasing 79% of patients having somatic findings that guide clinical care. The study also highlights the role of germline variants in tumor formation and hereditary cancer predisposition syndromes.
Scientists at St. Jude Children's Research Hospital have discovered a connection between the process that causes oil and vinegar to separate in salad dressing and solid tumors like prostate and breast cancer. The study found mutations in the tumor suppressor gene SPOP contribute to cancer by disrupting liquid-liquid phase separation, l...
Researchers at St. Jude Children's Research Hospital created a massive database of gene activity in individual cells during embryonic development and after birth, enabling scientists to trace specific developmental trajectories in the cerebellum. The analysis will aid understanding of brain development and provide a foundation for unde...
Geneticists at St. Jude Children's Research Hospital have discovered a previously unknown cell growth mechanism that makes many cancers resistant to rapamycin drugs. mTORC3, a novel complex, was found to be responsible for this resistance and offers a new target for anticancer drug development.
Researchers have identified mutations defining two common subtypes of MPAL, B/myeloid and T/myeloid, and shown that some patients may benefit from targeted therapies. The study provides a genetically based framework for designing clinical trials to develop more effective treatments.
Researchers at St. Jude Children's Research Hospital discovered that unconventional T cells play a crucial role in protecting infants from severe flu complications by promoting lung cell repair. This immune response differs from adults and may provide a new target for therapies to ease flu symptoms in infants.
Researchers identified vulnerabilities to target in a high-risk pediatric tumor, rhabdomyosarcoma, through an integrated analysis of cellular origins and epigenetic changes. The study promotes precision medicine by prioritizing drug development and highlighting the importance of preclinical models in streamlining treatment strategies.
A St. Jude Children's Research Hospital study found that over half of pediatric central nervous system tumor survivors do not achieve complete independence as adults. Cognitive impairment and physical performance limitations are strong predictors of non-independence.
A study by St. Jude Children's Research Hospital found that 65% of adult childhood cancer survivors reported financial challenges, including reduced health-related quality of life and increased risk of depression and suicidal thoughts. The researchers recommend routine screening for financial hardship to address these issues.
A study by St. Jude Children's Research Hospital and UCSF identified germline mutations in the genes SAMD9 or SAMD9L as responsible for a rare bone marrow disorder, myelodysplasia and leukemia syndrome with monosomy 7. The research found that some children with these mutations can spontaneously recover normal bone marrow function witho...
Researchers discover mTORC1 regulates cell growth and metabolism in developing T cells, favoring development of unconventional T cells. Disrupting mTORC1 leads to metabolic changes, altering T cell fate.
A significant portion of adult childhood cancer survivors are unconcerned about their future health and developing new cancers. Despite increased risk, many survivors underestimate their risks due to lack of understanding or awareness.
A rigorous study found that ethanol-lock therapy, widely used to reduce bloodstream infections, was ineffective in preventing new or recurring infections in young cancer patients with central venous catheters. The treatment was associated with increased complications, including catheter blockages and hospitalization.
Researchers at St. Jude Children's Research Hospital have identified a hidden driver, kinases Mst1 and Mst2, that regulates the function of different dendritic cell subsets and primes anti-tumor T cells. This discovery provides clues for new treatment strategies by modulating dendritic cell activity to shape the immune response.
St. Jude Children's Research Hospital is launching St. Jude Global, a $100M initiative aiming to increase access to care for children with cancer globally within the next decade. The program focuses on education, capacity building, and research to improve childhood cancer survival rates worldwide.
A team of St. Jude researchers discovered a medulloblastoma subtype that can be treated with reduced-intensity chemotherapy, improving survival rates for infants. The study found that 75% of patients with the subtype were alive five years after diagnosis, with low-risk patients having even better outcomes.
Researchers have identified six genes associated with an increased risk of developing medulloblastoma, a common childhood brain tumor. Genetic screening guidelines have been developed to help patients understand their lifetime cancer risk and manage their care.
Researchers identified a fourth gene, IKZF1, associated with childhood leukemia predisposition, expanding cancer screening options. Germline variants in IKZF1 increase the risk of developing B-cell acute lymphoblastic leukemia (ALL), a common pediatric cancer.
Researchers worldwide can now access the world's largest public repository of pediatric cancer genomics data via St. Jude Cloud. The platform offers accelerated data mining, analysis, and visualization capabilities, enabling faster progress toward cures for catastrophic diseases of childhood. By harnessing collective power, global rese...
St. Jude Children's Research Hospital investigators present research on cloud computing, exhausted T cells, breast cancer risk in childhood cancer survivors and clinical trial design for CAR-T therapy in solid tumors. The platform St. Jude Cloud provides unique analysis tools and visualizations of pediatric cancer genomics data.
Research from St. Jude Children's Research Hospital found that leukemia itself may increase the risk of long-term neurocognitive problems, even before treatment starts. Elevated biomarkers in cerebrospinal fluid indicate injury to brain cells, suggesting a complex interaction among genetics, treatment intensity, and other factors.
A new study found that adolescent and young adult cancer survivors have more available resources for emotional and practical support as well as advice on weight and physical activity. The study also showed a correlation between the strength of social networks and better coping skills.
A new study from St. Jude Children's Research Hospital and the American University of Beirut Medical Center demonstrates effective childhood cancer treatment in a refugee setting. The institution adapted its services to prioritize curable cases, showcasing a viable model for crisis response.
A comprehensive genomic analysis of childhood cancer reveals that children and adults have different mutated genes driving their disease, underscoring the need for pediatric-specific precision therapies. The study found that only 45% of the mutated genes 'driving' cancer in children are the same as those in adults.
The discovery of nucleophosmin's self-interaction mechanism could advance understanding of ALS and acute myeloid leukemia. Nucleophosmin plays a critical role in regulating the construction of ribosomes, which assemble proteins using RNA genetic code.
Researchers identified mechanisms driving 10% of high-risk neuroblastoma cases and showed c-MYC hijacks DNA to drive its own expression. The findings may help develop more effective therapies, including precision medicines. High-risk neuroblastoma has a poorer prognosis, but the study provides new insights into its development.